SLC35B4

Summary

SLC35B4 (solute carrier family 35 member B4, HGNC:20584) is a protein-coding gene on chromosome 7q33, encoding Nucleotide sugar transporter SLC35B4 (Q969S0). Antiporter that transports nucleotide sugars across the endoplasmic reticulum (ER) membrane in exchange for another nucleotide sugar.

Glycosyltransferases, such as SLC35B4, transport nucleotide sugars from the cytoplasm where they are synthesized, to the Golgi apparatus where they are utilized in the synthesis of glycoproteins, glycolipids, and proteoglycans (Ashikov et al., 2005 [PubMed 15911612]).

Source: NCBI Gene 84912 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 55 total
• MANE Select transcript: NM_032826

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20584
Approved symbol	SLC35B4
Name	solute carrier family 35 member B4
Location	7q33
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14697, YEA4
Ensembl gene	ENSG00000205060
Ensembl biotype	protein_coding
OMIM	610923
Entrez	84912

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000378509, ENST00000416907, ENST00000466599, ENST00000470969, ENST00000966638, ENST00000966639, ENST00000966640, ENST00000966641, ENST00000966642

RefSeq mRNA: 1 — MANE Select: NM_032826 NM_032826

CCDS: CCDS34756

Canonical transcript exons

ENST00000378509 — 10 exons

Exon	Start	End
ENSE00001477777	134289332	134295079
ENSE00001862876	134316675	134316930
ENSE00003516566	134306672	134306774
ENSE00003571149	134300152	134300261
ENSE00003579802	134301761	134301821
ENSE00003589580	134309366	134309479
ENSE00003616199	134304805	134304854
ENSE00003650607	134296391	134296466
ENSE00003654313	134302029	134302110
ENSE00003669927	134299523	134299598

Expression profiles

Bgee: expression breadth ubiquitous, 240 present calls, max score 91.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.4660 / max 106.0427, expressed in 1784 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
86311	8.8247	1760
86310	4.6414	1472

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar vermis	UBERON:0004720	91.12	gold quality
middle temporal gyrus	UBERON:0002771	91.07	gold quality
kidney epithelium	UBERON:0004819	90.88	gold quality
Brodmann (1909) area 23	UBERON:0013554	89.37	gold quality
endothelial cell	CL:0000115	88.77	gold quality
placenta	UBERON:0001987	88.58	gold quality
pigmented layer of retina	UBERON:0001782	87.43	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.72	gold quality
tibia	UBERON:0000979	86.43	gold quality
lateral nuclear group of thalamus	UBERON:0002736	85.89	gold quality
superior frontal gyrus	UBERON:0002661	85.76	gold quality
postcentral gyrus	UBERON:0002581	85.72	gold quality
parietal lobe	UBERON:0001872	85.61	gold quality
adrenal tissue	UBERON:0018303	85.43	gold quality
primary visual cortex	UBERON:0002436	84.84	gold quality
epithelial cell of pancreas	CL:0000083	84.72	gold quality
occipital lobe	UBERON:0002021	84.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.49	gold quality
entorhinal cortex	UBERON:0002728	84.44	gold quality
cerebellum	UBERON:0002037	84.29	gold quality
stromal cell of endometrium	CL:0002255	83.95	gold quality
cerebellar cortex	UBERON:0002129	83.80	gold quality
cerebellar hemisphere	UBERON:0002245	83.61	gold quality
prefrontal cortex	UBERON:0000451	83.35	gold quality
visceral pleura	UBERON:0002401	83.13	gold quality
liver	UBERON:0002107	83.10	gold quality
Brodmann (1909) area 46	UBERON:0006483	83.04	gold quality
kidney	UBERON:0002113	82.97	gold quality
right hemisphere of cerebellum	UBERON:0014890	82.87	gold quality
metanephros	UBERON:0000081	82.61	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.98

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

159 targeting SLC35B4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197

Literature-anchored findings (GeneRIF, showing 7)

• Transport capabilities for UDP-Glc and UDP-Xyl were determined with Golgi vesicles isolated from transformed cells (PMID:15911612)
• Decreased SLC35B4 expression led to increased gluconeogenesis in HepG2 cells. (PMID:21507882)
• subcellular localization of SLC35B4 (PMID:21918738)
• SLC35B4 single nucleotide polymorphism rs1646724 was associated with recurrence in patients with localized disease and survival in patients with advanced prostate cancer. (PMID:29682886)
• Glucose levels activate SLC35B4 expression. This triggers a downstream effect via Hsp60 and other proteins. We hypothesize that the downstream effect on the proteins is mediated via altering the glycosylation pattern inside liver cells (PMID:29867058)
• Our data showed that knock-out of the SLC35B4 gene does not affect major UDP-Xyl- and UDP-GlcNAc-dependent glycosylation pathways. (PMID:30458018)
• A novel YAP1/SLC35B4 axis promotes gastric cancer (GC) development and progression, and this axis could be a potential candidate for prognosis and therapeutics in GC. (PMID:31175271)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc35b4	ENSDARG00000071087
mus_musculus	Slc35b4	ENSMUSG00000018999
rattus_norvegicus	Slc35b4	ENSRNOG00000008851
drosophila_melanogaster	Efr	FBGN0029849
drosophila_melanogaster	CG14511	FBGN0039641
caenorhabditis_elegans		WBGENE00017480

Paralogs (3): SLC35B1 (ENSG00000121073), SLC35B3 (ENSG00000124786), SLC35B2 (ENSG00000157593)

Protein

Protein identifiers

Nucleotide sugar transporter SLC35B4 — Q969S0 (reviewed: Q969S0)

Alternative names: Solute carrier family 35 member B4, UDP-xylose and UDP-N-acetylglucosamine transporter, YEA4 homolog

All UniProt accessions (2): Q969S0, F8WAW0

UniProt curated annotations — full annotation on UniProt →

Function. Antiporter that transports nucleotide sugars across the endoplasmic reticulum (ER) membrane in exchange for another nucleotide sugar. May couple UDP-alpha-D-glucuronate (UDP-GlcA) or UDP-alpha-D-xylose (UDP-Xyl) efflux to UDP-alpha-D-glucuronate (UDP-GlcA) influx into the ER lumen, which in turn stimulates glucuronidation and excretion of endobiotics and xenobiotics. Has UDP-GlcA:UDP-GlcNAc antiporter activity. Has UDP-GlcA:UDP-GlcNAc antiporter activity.

Subcellular location. Endoplasmic reticulum membrane.

Similarity. Belongs to the nucleotide-sugar transporter family. SLC35B subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q969S0-1	1	yes
Q969S0-2	2
Q969S0-3	3

RefSeq proteins (1): NP_116215* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013657	HUT1	Family

Pfam: PF08449

Catalyzed reactions (Rhea), 2 shown:

• UDP-N-acetyl-alpha-D-glucosamine(in) + UDP-alpha-D-glucuronate(out) = UDP-N-acetyl-alpha-D-glucosamine(out) + UDP-alpha-D-glucuronate(in) (RHEA:73703)
• UDP-alpha-D-xylose(in) + UDP-alpha-D-glucuronate(out) = UDP-alpha-D-xylose(out) + UDP-alpha-D-glucuronate(in) (RHEA:74831)

UniProt features (23 total): transmembrane region 11, splice variant 4, sequence conflict 4, mutagenesis site 2, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q969S0-F1	86.73	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (2):

Position	Phenotype
329	results in loss of er retention signal and relocalization at the golgi apparatus.
330	results in loss of er retention signal and relocalization at the golgi apparatus.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-727802	Transport of nucleotide sugars
R-HSA-382551	Transport of small molecules
R-HSA-425397	Transport of vitamins, nucleosides, and related molecules
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 134 (showing top): MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_MONOSACCHARIDE_BIOSYNTHETIC_PROCESS, GOMF_NUCLEOBASE_CONTAINING_COMPOUND_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOBP_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_REGULATION_OF_GLUCOSE_METABOLIC_PROCESS, GOBP_GLUCOSE_METABOLIC_PROCESS, GOBP_REGULATION_OF_CARBOHYDRATE_BIOSYNTHETIC_PROCESS, GOBP_MONOSACCHARIDE_METABOLIC_PROCESS, BIDUS_METASTASIS_UP, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN

GO Biological Process (4): regulation of gluconeogenesis (GO:0006111), UDP-xylose transmembrane transport (GO:0015790), UDP-N-acetylglucosamine transmembrane transport (GO:1990569), transmembrane transport (GO:0055085)

GO Molecular Function (3): UDP-N-acetylglucosamine transmembrane transporter activity (GO:0005462), UDP-xylose transmembrane transporter activity (GO:0005464), protein binding (GO:0005515)

GO Cellular Component (6): Golgi membrane (GO:0000139), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), endomembrane system (GO:0012505), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Transport of vitamins, nucleosides, and related molecules	1
SLC-mediated transmembrane transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
pyrimidine nucleotide-sugar transmembrane transport	2
pyrimidine nucleotide-sugar transmembrane transporter activity	2
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
gluconeogenesis	1
regulation of glucose metabolic process	1
regulation of carbohydrate biosynthetic process	1
transport	1
cellular process	1
UDP-N-acetylglucosamine transmembrane transport	1
UDP-xylose transmembrane transport	1
binding	1
Golgi apparatus	1
bounding membrane of organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
vacuole	1
plasma membrane	1

Protein interactions and networks

STRING

842 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC35B4	SLC35A3	Q9Y2D2	920
SLC35B4	SLC35D2	Q76EJ3	918
SLC35B4	SLC35D1	Q9NTN3	894
SLC35B4	SLC35D3	Q5M8T2	883
SLC35B4	SLC35H1	Q9NQQ7	715
SLC35B4	SLC35A5	Q9BS91	673
SLC35B4	SLC35C1	Q96A29	649
SLC35B4	SLC35E1	Q96K37	607
SLC35B4	SLC35A1	P78382	566
SLC35B4	SLC35A4	Q96G79	554
SLC35B4	SLC35F1	Q5T1Q4	528
SLC35B4	SLC35F6	Q8N357	491
SLC35B4	SLC35B2	Q8TB61	474
SLC35B4	CHID1	Q9BWS9	453
SLC35B4	COASY	Q13057	443

IntAct

103 interactions, top by confidence:

A	B	Type	Score
CREB3L1	SLC35B4	psi-mi:“MI:0915”(physical association)	0.720
SLC35B4	CREB3L1	psi-mi:“MI:0915”(physical association)	0.720
SLC35B4	FFAR2	psi-mi:“MI:0915”(physical association)	0.560
SLC35B4	PDZK1IP1	psi-mi:“MI:0915”(physical association)	0.560
SLC35B4	PVR	psi-mi:“MI:0915”(physical association)	0.560
SLC35B4	FAM210B	psi-mi:“MI:0915”(physical association)	0.560
KASH5	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
SLC35B4	TMEM237	psi-mi:“MI:0915”(physical association)	0.560
SCARA5	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
SLC35B4	RHBDL2	psi-mi:“MI:0915”(physical association)	0.560
LHFPL5	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
TYROBP	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
STOM	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
CISD2	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
CLDN5	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
ERP29	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
TBXA2R	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
SLC35B4	VSIR	psi-mi:“MI:0915”(physical association)	0.560
EBAG9	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
SLC35B4	ERGIC3	psi-mi:“MI:0915”(physical association)	0.560
MUC1	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
FFAR2	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
PDZK1IP1	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560
PVR	SLC35B4	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (143): CREB3L1 (Two-hybrid), SLC35B4 (Affinity Capture-RNA), SLC35B4 (Proximity Label-MS), SLC35B4 (Two-hybrid), SLC35B4 (Synthetic Lethality), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid), SLC35B4 (Two-hybrid)

ESM2 similar proteins: A1C9R4, A1CZJ3, A1DA52, A2R9P4, A3LWX1, A4RM13, A5DIN8, A6RJQ8, A6ZTW6, A7E558, A7TES5, A7TR80, A8N9T6, B0DI84, B0Y384, B3LHR7, B3LS51, B5VHH5, C7GSI5, C7GUZ7, C8Z742, C8Z830, P0CE11, P0CS02, P0CS03, P0CS04, P0CS05, P40107, Q0CA27, Q0UG89, Q1DTI4, Q2AAF6, Q2HA88, Q2UTL1, Q4WTQ6, Q5A477, Q5AQY2, Q5AS82, Q5R8M3, Q6C0U0

Diamond homologs: O74750, P40004, Q00974, Q5R8M3, Q7ZW46, Q869W7, Q8CIA5, Q95KB4, Q969S0, Q9W429

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1558 predictions. Top by Δscore:

Variant	Effect	Δscore
7:134296333:T:A	donor_gain	1.0000
7:134299522:CCAGA:C	donor_gain	1.0000
7:134299595:CGTG:C	acceptor_gain	1.0000
7:134299599:C:CC	acceptor_gain	1.0000
7:134300150:A:AC	donor_gain	1.0000
7:134300151:C:CC	donor_gain	1.0000
7:134300168:T:TA	donor_gain	1.0000
7:134306670:A:AC	donor_gain	1.0000
7:134306671:C:CC	donor_gain	1.0000
7:134306671:CG:C	donor_gain	1.0000
7:134306671:CGG:C	donor_gain	1.0000
7:134306671:CGGA:C	donor_gain	1.0000
7:134306671:CGGAT:C	donor_gain	1.0000
7:134306770:AGTAC:A	acceptor_gain	1.0000
7:134306771:GTAC:G	acceptor_gain	1.0000
7:134306772:TAC:T	acceptor_gain	1.0000
7:134306775:C:CC	acceptor_gain	1.0000
7:134306775:C:CG	acceptor_loss	1.0000
7:134306776:T:C	acceptor_loss	1.0000
7:134309360:CCATA:C	donor_loss	1.0000
7:134309361:CATAC:C	donor_loss	1.0000
7:134309363:TA:T	donor_loss	1.0000
7:134309364:ACCTT:A	donor_loss	1.0000
7:134309365:C:A	donor_loss	1.0000
7:134310351:T:TA	donor_gain	1.0000
7:134310354:T:TA	donor_gain	1.0000
7:134299597:TG:T	acceptor_gain	0.9900
7:134299601:A:C	acceptor_gain	0.9900
7:134300146:GCTT:G	donor_loss	0.9900
7:134300147:CTTAC:C	donor_loss	0.9900

AlphaMissense

2187 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:134294989:G:C	S280R	1.000
7:134294989:G:T	S280R	1.000
7:134294991:T:G	S280R	1.000
7:134294987:A:G	L281P	0.999
7:134295003:G:T	R276S	0.999
7:134295070:G:C	C253W	0.999
7:134295071:C:T	C253Y	0.999
7:134302067:C:G	G130R	0.999
7:134302067:C:T	G130R	0.999
7:134306735:G:C	S77R	0.999
7:134306735:G:T	S77R	0.999
7:134306737:T:G	S77R	0.999
7:134309437:A:C	F40L	0.999
7:134309437:A:T	F40L	0.999
7:134309439:A:G	F40L	0.999
7:134294912:C:T	G306E	0.998
7:134294913:C:G	G306R	0.998
7:134294913:C:T	G306R	0.998
7:134294934:C:G	G299R	0.998
7:134295002:C:G	R276P	0.998
7:134295005:A:G	L275P	0.998
7:134295050:A:G	L260P	0.998
7:134295055:A:C	F258L	0.998
7:134295055:A:T	F258L	0.998
7:134295057:A:G	F258L	0.998
7:134295072:A:G	C253R	0.998
7:134296402:G:C	N246K	0.998
7:134296402:G:T	N246K	0.998
7:134302063:A:T	I131K	0.998
7:134302066:C:T	G130E	0.998

dbSNP variants (sampled 300 via entrez): RS1000055467 (7:134314811 G>C), RS1000061829 (7:134308754 C>T), RS1000411109 (7:134318157 T>A), RS1000559329 (7:134319401 T>A,C), RS1000571595 (7:134300961 G>A,C), RS1000664086 (7:134292901 C>G), RS1000672389 (7:134307022 C>T), RS1000714120 (7:134311809 T>A,C), RS1000740359 (7:134305405 T>C), RS1001129295 (7:134318696 C>T), RS1001265041 (7:134318950 T>C,G), RS1001273880 (7:134296709 G>T), RS1001388207 (7:134310905 G>A), RS1001470865 (7:134317207 A>G), RS1001585082 (7:134317770 G>C)

Disease associations

OMIM: gene MIM:610923 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004599_59	Mean platelet volume	4.000000e-20
GCST009645_2	Systolic blood pressure response to thiazide and thiazide-like diuretics in hypertension	5.000000e-08
GCST90002395_702	Mean platelet volume	4.000000e-36
GCST90002400_55	Plateletcrit	5.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006944	systolic blood pressure change measurement
EFO:0007985	platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC35 family of nucleotide sugar transporters

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	4
Cyclosporine	decreases expression	2
triphenyl phosphate	affects expression	1
methylparaben	decreases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
Temozolomide	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	decreases expression	1
Diuron	decreases expression	1
Environmental Pollutants	affects expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Zidovudine	increases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4M3	HCT116-SLC35B4-KO-c10	Cancer cell line	Male
CVCL_D4M4	HCT116-SLC35B4-KO-c7	Cancer cell line	Male
CVCL_TN12	HAP1 SLC35B4 (-) 1	Cancer cell line	Male
CVCL_TN13	HAP1 SLC35B4 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.